(VIANEWS) – RYANAIR HOLD. PLC (RYA.IR), BOIRON (BOI.PA), ALTRI SGPS (ALTR.LS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. RYANAIR HOLD. PLC (RYA.IR)
38.7% sales growth and 24.39% return on equity
Ryanair Holdings plc, together with its subsidiaries, provides scheduled-passenger airline services in Ireland, the United Kingdom, Italy, Spain, Germany, and other European countries. It is also involved in the provision of various ancillary services, such as non-flight scheduled and Internet-related services; in-flight sale of beverages, food, duty-free, and merchandise; and marketing of car hire and accommodation services, and travel insurance through its website and mobile app. In addition, the company offers aircraft and passenger handling, ticketing, and maintenance and repair services; and markets car parking, fast-track, airport transfers, attractions, and activities on its website and mobile app, as well as sells gift vouchers. As of June 30, 2022, it had a principal fleet of approximately 483 Boeing 737 aircrafts and 29 Airbus A320 aircrafts; and offered approximately 3,000 short-haul flights per day serving approximately 225 airports. Ryanair Holdings plc was founded in 1985 and is headquartered in Swords, Ireland.
Earnings Per Share
As for profitability, RYANAIR HOLD. PLC has a trailing twelve months EPS of €-0.58.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.39%.
Sales Growth
RYANAIR HOLD. PLC’s sales growth for the next quarter is 38.7%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 57.3%, now sitting on 10.1B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 150% and a drop 144.4% for the next.
More news about RYANAIR HOLD. PLC.
2. BOIRON (BOI.PA)
17.3% sales growth and 8.13% return on equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €1.5.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 26.25. Meaning, the purchaser of the share is investing €26.25 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.13%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 1, 2023, the estimated forward annual dividend rate is 1.1 and the estimated forward annual dividend yield is 2.76%.
More news about BOIRON.
3. ALTRI SGPS (ALTR.LS)
16% sales growth and 24.22% return on equity
Altri, SGPS, S.A. produces and sells bleached eucalyptus pulp in Portugal and internationally. It offers bleached eucalyptus kraft pulp for use in a range of papers, such as tissues, and printing and writing papers; and dissolving pulp for use in textile production. The company is also involved timber commercialization; forest management; the production of energy from forest resources, such as industrial cogeneration from black liquor and biomass; real estate activities; and production of plants in nurseries, as well as the provision of services related with forests and landscapes. The company was incorporated in 2005 and is headquartered in Porto, Portugal.
Earnings Per Share
As for profitability, ALTRI SGPS has a trailing twelve months EPS of €0.17.
PE Ratio
ALTRI SGPS has a trailing twelve months price to earnings ratio of 28.21. Meaning, the purchaser of the share is investing €28.21 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.22%.
More news about ALTRI SGPS.
4. FRØY (FROY.OL)
14% sales growth and 10.16% return on equity
Frøy ASA provides integrated service to the aquaculture industry in Norway. The company offers wellboat services, sea freight, de-lice and treatment, mooring and laying, ring washing and cage services, net washing and mending, inspection and certification, bottom mapping and documentation, slep, diving and ROV, and control system. It owns and operates 18 wellboats, 60 aqua service vessels, 3 feed transport vessels, and 13 local offices along the Norwegian coast. The company was founded in 2019 and is headquartered in Sistranda, Norway.
Earnings Per Share
As for profitability, FRØY has a trailing twelve months EPS of kr98.71.
PE Ratio
FRØY has a trailing twelve months price to earnings ratio of 0.65. Meaning, the purchaser of the share is investing kr0.65 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.16%.
Sales Growth
FRØY’s sales growth is 18.9% for the ongoing quarter and 14% for the next.
Moving Average
FRØY’s value is above its 50-day moving average of kr61.08 and way above its 200-day moving average of kr48.48.
More news about FRØY.
5. WEBSTEP (WSTEP.OL)
11.6% sales growth and 11.66% return on equity
Webstep ASA, together with its subsidiaries, provides information technology (IT) consultancy services to public and private businesses in Norway and Sweden. The company offers digitalization, cloud migration and integration, Internet of Things, machine learning, IT security, robotics, and analytics. Its services include consulting, digitalization, .Net, Java, open source, full stack, front and back end, user experience, integration, mobility, cloud apps, machine learning, business intelligence, big data, data warehousing, virtual robotics, Devops, application service management, and data science services; and cloud computing, cloud services, integration, sensor technology, product and service development, Beacons, enterprise user experience, web analysis, design team, Amazon Web, Azure, prediction, AI, mobility predictive modelling, predictive modelling, hackathon, business analysis, and search engine optimization services. The company serves banking, finance and insurance, public administration, agriculture and food production, IT and telecommunication, commerce, and transportation industries. The company was founded in 2000 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, WEBSTEP has a trailing twelve months EPS of kr1.38.
PE Ratio
WEBSTEP has a trailing twelve months price to earnings ratio of 22.51. Meaning, the purchaser of the share is investing kr22.51 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.66%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 40% and 68.6%, respectively.
Sales Growth
WEBSTEP’s sales growth is 16.7% for the current quarter and 11.6% for the next.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Apr 29, 2022, the estimated forward annual dividend rate is 1.7 and the estimated forward annual dividend yield is 6.42%.
Volume
Today’s last reported volume for WEBSTEP is 3900 which is 82.81% below its average volume of 22689.
More news about WEBSTEP.
6. EQUASENS (EQS.PA)
11.3% sales growth and 28.59% return on equity
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.59%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.3%, now sitting on 202.74M for the twelve trailing months.
Yearly Top and Bottom Value
EQUASENS’s stock is valued at €70.90 at 22:20 EST, way under its 52-week high of €90.60 and way higher than its 52-week low of €57.80.
More news about EQUASENS.
7. SPBK1 RINGERIKE (RING.OL)
11.1% sales growth and 9.9% return on equity
SpareBank 1 Ringerike Hadeland provides various banking products and services to private and corporate customers in Norway. The company offers saving, current, deposit, and currency accounts; vehicle, house and travel, and animal insurance products, as well as life, child, disability, critical illness, accident, health, and business and personal insurance products; mobile and online banking services; and debit and credit cards. It also provides mortgages; car, boat, and other vehicles; consumer and other loans; and bank guarantees, corporate and construction loans, liquidity loans with a government guarantee, and operating credit for agriculture, as well as factoring, leasing, and overdraft services. In addition, the company offers services for buying and selling property; accounting services; pension products; and savings and investment products. The company was founded in 1833 and is based in Hønefoss, Norway.
Earnings Per Share
As for profitability, SPBK1 RINGERIKE has a trailing twelve months EPS of kr22.77.
PE Ratio
SPBK1 RINGERIKE has a trailing twelve months price to earnings ratio of 14.14. Meaning, the purchaser of the share is investing kr14.14 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.9%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.9%, now sitting on 931.3M for the twelve trailing months.
More news about SPBK1 RINGERIKE.
8. MEDISTIM (MEDI.OL)
10.2% sales growth and 33.83% return on equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr3.84.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 73.94. Meaning, the purchaser of the share is investing kr73.94 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.83%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.6%, now sitting on 491.94M for the twelve trailing months.
Moving Average
MEDISTIM’s value is way higher than its 50-day moving average of kr237.47 and way higher than its 200-day moving average of kr245.35.
Volume
Today’s last reported volume for MEDISTIM is 456 which is 95.74% below its average volume of 10717.
Sales Growth
MEDISTIM’s sales growth is 26% for the ongoing quarter and 10.2% for the next.
More news about MEDISTIM.
